Arcturus Therapeutics

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/JoePayne_LanguageProficiency_V3_1.mp4?time=1669765209
arabic
(عربى)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/MaherA_LanguageProficiency_V3_1.mp4?time=1669765209
chinese
(中文)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_BelleBao.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/BelleBao_LanguageProficiency__V3_1.mp4?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_HowardYu.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/HowardYu_LanguageProficiency_V3_1.mp4?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_YurongGuo.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/YurongGuo_LanguageProficiency_V3_1.mp4?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_XuefengGuo.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/XuefengGuo_LanguageProficiency_V3_1.mp4?time=1669765209
english
(British)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/MikeHodges_LanguageProficiency_V3_1.mp4?time=1669765209
farsi
(فارسی)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2021/01/NedaSafarzadeh_LanguageProficiency_V4.mp4?time=1669765209
french
(Français)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4?time=1669765209
german
(deutsch)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4?time=1669765209
hebrew
(עִברִית)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_NoaScott.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/NoaScott_LanguageProficiency_V3_1.mp4?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_TamarGrossman.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/TamarGrossman_LanguageProficiency_V3_1.mp4?time=1669765209
hindi
(हिन्दी)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/PriyaKarmali_LanguageProficiency_V3_1.mp4?time=1669765209
italian
(italiano)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_CristianoSacchetti.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/CristianoSacchetti_LanguageProficiency_V3_1.mp4?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/thumbnail_GiulioCattarossi.jpg?time=1669765209,https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/GiulioCattarossi_LanguageProficiency_V3_1.mp4?time=1669765209
Japanese
(日本語)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/09/Kiyoshi_Tachikawa_v2.mp4?time=1669765209
korean
(한국어)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/JaeHeonKim_LanguageProficiency_V3_1.mp4?time=1669765209
portuguese
(Português)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/RamonDiazTrelles_LanguageProficiency_V3_1.mp4?time=1669765209
spanish
(español)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4?time=1669765209
vietnamese
(Tiếng Việt)
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/07/HannahHuynh_LanguageProficiency_V3_1.mp4?time=1669765209

News & Events

November 9, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
November 1, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
October 26, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
September 27, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
September 1, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
August 31, 2022
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
August 18, 2022
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
August 9, 2022
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
August 1, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
February 28, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
February 16, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
February 8, 2022
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
January 25, 2022
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
January 24, 2022
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

LUNAR® Mechanism of Delivery